(Press-News.org) Huntsman Cancer Institute research highlights shine the spotlight on new discoveries and cutting-edge cancer research. This past month, researchers found a better treatment practice for patients who have melanoma. They also created a model for adrenocortical carcinoma, a rare cancer that originates in the outer portion of the adrenal gland. Learn more about a new brain cancer medication being fast-tracked for FDA approval and how Huntsman Cancer Institute was selected to conduct clinical trials for cancer patients with HIV.
Clinical trial suggests changes to melanoma patient care
A study recounting a clinical trial published in The New England Journal of Medicine shows that three cycles of immunotherapy before surgery, followed by immunotherapy for one year, decreases the likelihood of stage III melanoma recurrence. This strategy improved outcomes compared to the current standard of care.
Immunotherapy enables the patient’s immune system to have a stronger response to cancer. John Hyngstrom, MD, oncology surgeon at Huntsman Cancer Institute and associate professor of surgical oncology at the University of Utah, was the site principal investigator of the Southwest Oncology Group 1801 trial at Huntsman Cancer Institute.
Researchers study adrenocortical carcinoma and find differences between sexes
A new study is providing hope for those with a rare adrenal cancer. The research, published in the journal Nature Aging, uncovered new information about adrenocortical carcinoma, a rare, highly-aggressive cancer with no effective therapies. Huntsman Cancer Institute researchers Kate Warde, PhD, principal investigator Kaitlin Basham, PhD, assistant professor of oncological sciences at the University of Utah, and fellow researchers found that in their model, female mice were more likely to develop adrenocortical carcinoma compared with males.
This was particularly striking because in humans, this cancer is also more common in women than men. The researchers found that male mice, who were more protected from aggressive adrenal tumors, had a stronger myeloid immune response. This protective immune response in males was enhanced by male sex hormones called androgens. This study has opened up exciting avenues for further research and new potential therapeutic interventions to improve cancer care.
First oral medication to treat brain cancer in over 20 years shown to be effective
Researchers found the first oral medication in over two decades to treat low-grade gliomas, slows their growth. Low-grade gliomas are a type of slow-growing brain tumor. The medication in this phase III clinical trial targets a mutation to help control the cancer. Huntsman Cancer Institute was a top institution in providing patients to this global clinical trial with neuro-oncologist Joe Mendez, MD, also an assistant professor in the department of neurosurgery at the University of Utah, as the principal investigator.
The findings of the clinical trial show that the medication slows the tumor growing, and therefore could delay the treatment of more aggressive therapies, like radiation and chemotherapy. Because of these results, researchers and doctors will be working on getting a fast-tracked approval from the U.S. Food and Drug Administration (FDA).
AIDS Malignancy Consortium brings clinical trials to patients in the Mountain West
Huntsman Cancer Institute is now an AIDS Malignancy Consortium site, a National Cancer Institute-supported group that provides clinical trials to cancer patients with human immunodeficiency virus (HIV). Previously, patients with HIV had limited access to cancer clinical trials. This international clinical trial cooperative group is closing the gap. Gita Suneja, MD, MS, physician-scientist at Huntsman Cancer Institute and associate professor of radiation oncology at the University of Utah, is the lead investigator of this initiative that will greatly benefit people living with HIV in the Area We Serve.
###
About Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute at the University of Utah (the U) is the official cancer center of Utah and the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West. The institute is leading the world in scientific discovery, and turning it into unsurpassed cancer care, transforming hope into a reality. Huntsman Cancer Institute focuses on delivering a cancer-free frontier to Utah, Idaho, Montana, Nevada, and Wyoming (The Area We Serve). Huntsman Cancer Institute is home to over 325 clinical trials, with 250 research teams studying cancer at any given time and more genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Huntsman Cancer Institute’s scientists are world renown for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient’s unique tumor. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.
END
Huntsman Cancer Institute May research highlights
2023-06-01
ELSE PRESS RELEASES FROM THIS DATE:
Postdoctoral research experience gets major boost at Pennington Biomedical
2023-06-01
Former Pennington Biomedical Research Center Executive Director Dr. Claude Bouchard and his wife, Monique Chagnon, were celebrated at a luncheon on Tuesday, May 30, for their generous gift to enhance the postdoctoral researcher experience at Pennington Biomedical.
As one of the world’s foremost researchers in the genetics of obesity and related diseases, including type 2 diabetes and hypertension, the Bouchard laboratory has trained about 40 postdoctoral researchers throughout his career.
“I became very conscious that postdocs are critical to the success of the scientific research enterprise. They work hard, they ...
New liver dialysis device shows potential to resolve liver failure in patients with acute-on-chronic liver failure
2023-06-01
Amsterdam, June 1, 2023 – Acute-on-chronic liver failure (ACLF) occurs in 30% of hospitalized cirrhosis patients, leading to over one million deaths worldwide each year. Currently the only potential treatment for this condition is liver transplantation, which is available to very few patients. A first-in-human randomized controlled clinical trial using DIALIVE, a novel liver dialysis device, demonstrated its potential as a disease-modifying therapy and resolved liver failure significantly faster and in a greater proportion of patients ...
Liver dialysis device proved safe and effective for treating severe liver failure
2023-06-01
The first successful in-patient trial of liver dialysis* has been completed by researchers from UCL, the Royal Free Hospital, UCL spin-out Yaqrit and their collaborators.
The DIALIVE device, invented by researchers at UCL’s Institute for Liver and Digestive Health, was found to be safe and was associated with substantial improvement in the severity of symptoms and organ function in a greater proportion of patients with acute-on-chronic liver failure (ACLF), when compared with patients receiving standard of care.
The next step will be a larger clinical trial, which if successful could see DIALIVE approved for clinical use within the next three years.
Worldwide, it is estimated that there ...
Xrays reveal ancient secrets about our prehistoric world this World Dinosaur Day
2023-06-01
Researchers are shedding light on our ancient prehistoric world using state-of-the art Xray technology. This World Dinosaur Day, scientists are sharing the bones which lay beneath the Harbury Icthyosau – providing clues to dinosaur anatomy, physiology and evolution.
The University's of Warwick’s Centre for Imaging, Metrology and Additive Technologies (CiMAT) group at WMG has employed its cutting-edge equipment to explore the anatomy and biology of the Harbury Icthyosaur, a large marine reptile which lived on the Earth hundreds of millions of years ...
Phototherapy device has potential to be a novel treatment for sleep complaints
2023-05-31
DARIEN, IL – Wearing a phototherapy device that emits near-infrared light is associated with potential therapeutic benefits for sleep and daytime functioning, according to a new study to be presented at the SLEEP 2023 annual meeting.
Results show that self-reported, sleep-related symptoms improved after three weeks of treatment. Participants in the active treatment group reported experiencing better sleep quality, feeling more refreshed and relaxed, and functioning better during the day.
“This novel phototherapy device — while ...
UC Irvine-led interdisciplinary team delves into a heated debate about humidity
2023-05-31
Irvine, Calif., May 31, 2023 – As climate change increases the severity, frequency and duration of heat waves around the world, researchers at the University of California, Irvine and other institutions are sounding an alarm about what they consider to be an added threat to human health: humidity.
Heat extremes increase the risk of illness and death, with the worst outcomes among people who are older, have chronic diseases, live in hot climates and are socioeconomically disadvantaged. In addition, humidity causes heat stress by making it harder for bodies to cool, but medical and public health experts still disagree about ...
Level of support for gender-neutral option on state IDs affected by political orientation, social context
2023-05-31
Key takeaways
As of June, 22 U.S. states and the District of Columbia will offer the opportunity for residents to select a gender-neutral marker on government-issued IDs.
UCLA sociologist Abigail Saguy found that LGBTQ+ and feminist activists support both the addition of a gender-neutral option and the removal of gender identifiers on IDs.
Conservative activists oppose both measures.
As of June, 22 states and the District of Columbia will allow residents to select a gender-neutral “X” marker, rather than “male” or “female,” on their driver’s licenses, ...
NIH scientists find treatment for rare genetic skin disorder
2023-05-31
Researchers at the National Institutes of Health and their colleagues have identified genomic variants that cause a rare and severe inflammatory skin disorder, known as disabling pansclerotic morphea, and have found a potential treatment. Scientists discovered that people with the disorder have an overactive version of a protein called STAT4, which regulates inflammation and wound healing. The work also identified a drug that targets an important feedback loop controlled by the STAT4 protein and significantly improves symptoms in these patients. The results were ...
UC hosts aerospace conference on artificial intelligence
2023-05-31
Aerospace experts from across North America are coming to the University of Cincinnati this week for a conference on artificial intelligence.
UC is playing host to the annual North American Fuzzy Information Processing Society's conference at UC's new Digital Futures building. It's an international research conference that will bring aerospace experts to Cincinnati to share the latest on artificial intelligence relating to drones, aviation, space exploration and other applications.
One of the conference sponsors, Thales, a French-based international holding company that engages in the manufacture, ...
$5M gift establishes Arts and Sciences outreach professorship
2023-05-31
CORNELL UNIVERSITY MEDIA RELATIONS OFFICE
FOR RELEASE: May 31, 2023
Rebecca Valli
cell: 607-793-1025
rv234@cornell.edu
$5M gift establishes Arts and Sciences outreach professorship
ITHACA, N.Y. – Bolstering its commitment to broader engagement, the College of Arts and Sciences has established the Winokur Professorship for the Public Understanding of Science and Mathematics.
Distinguished mathematician, award-winning teacher and well-known science communicator Steven Strogatz has been appointed as the inaugural holder of the chair. ...